Why this pain-killing opioid is spinning into a new company
May 23, 2019 at 17:29 PM EDT
Nektar's wholly owned subsidiary might relieve some pain if NKTR-181 finds it tough to win a recommendation in August from an FDA advisory committee yet also provide financial upside if its unique opioid is approved.
